Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mazdutide by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval
Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase I for Type 2 Diabetes. According...
Mazdutide by Eli Lilly and Co for Obesity: Likelihood of Approval
Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Obesity. According to GlobalData,...
Mazdutide by Eli Lilly and Co for Polycystic Ovarian Syndrome: Likelihood of Approval
Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Polycystic Ovarian Syndrome. According...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Mazdutide?
Mazdutide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity. According...
Risk adjusted net present value: What is the current valuation of Innovent Biologics's Mazdutide?
Mazdutide is a synthetic peptide commercialized by Innovent Biologics, with a leading Phase II program in Obesity. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Mazdutide?
Mazdutide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity. According...